Fisher Benjamin A, Allard Andrew, Dubey Shirish, Mankia Kulveer, Pratt Arthur G, Pallan Lalit
Rheumatology Research Group, Department of Inflammation and Ageing, School of Infection, Inflammation and Immunology, University of Birmingham, Birmingham, UK; Department of Rheumatology and NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Royal National Hospital for Rheumatic Diseases, Royal United Hospitals Bath NHSFT, Bath BA1 3NG, UK.
Clin Med (Lond). 2025 Aug 6;25(5):100496. doi: 10.1016/j.clinme.2025.100496.
Immune checkpoint inhibitors (ICI) used for the treatment of malignancy are associated with immune-related adverse events, which include inflammatory arthritis. ICI-induced inflammatory arthritis (ICI-IA) is a new clinical entity that may lead to functional impairment and may be persistent even after ICI cessation. We discuss the clinical features, investigation and differential diagnosis. Management needs to consider the safety of immunosuppression in the context of the underlying cancer, and current practice will be further informed by ongoing clinical trials.
用于治疗恶性肿瘤的免疫检查点抑制剂（ICI）与免疫相关不良事件有关，其中包括炎性关节炎。ICI诱导的炎性关节炎（ICI-IA）是一种新的临床实体，可能导致功能障碍，甚至在停用ICI后仍可能持续存在。我们讨论了其临床特征、检查及鉴别诊断。管理需要在潜在癌症的背景下考虑免疫抑制的安全性，正在进行的临床试验将为当前的实践提供进一步的依据。
